282 related articles for article (PubMed ID: 32045828)
1. Perceptions and concerns of hepatitis C reinfection following prison-wide treatment scale-up: Counterpublic health amid hepatitis C treatment as prevention efforts in the prison setting.
Lafferty L; Rance J; Grebely J; Dore GJ; Lloyd AR; Treloar C;
Int J Drug Policy; 2020 Mar; 77():102693. PubMed ID: 32045828
[TBL] [Abstract][Full Text] [Related]
2. The role of social capital in facilitating hepatitis C treatment scale-up within a treatment-as-prevention trial in the male prison setting.
Lafferty L; Rance J; Dore GJ; Lloyd AR; Treloar C
Addiction; 2021 May; 116(5):1162-1171. PubMed ID: 33006784
[TBL] [Abstract][Full Text] [Related]
3. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.
Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR
Addiction; 2020 May; 115(5):901-913. PubMed ID: 31633853
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C treatment as prevention in the prison setting: Assessments of acceptability of treatment scale up efforts by prison correctional and health personnel.
Lafferty L; Rance J; Dore GJ; Grebely J; Lloyd AR; Treloar C;
Int J Drug Policy; 2021 Dec; 98():103379. PubMed ID: 34311138
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.
Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ;
Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):533-546. PubMed ID: 33965006
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study.
Carson JM; Dore GJ; Lloyd AR; Grebely J; Byrne M; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Matthews GV; Hajarizadeh B;
Clin Infect Dis; 2022 Nov; 75(10):1809-1819. PubMed ID: 35362522
[TBL] [Abstract][Full Text] [Related]
7. Consensus recommendations on the management of hepatitis C in Australia's prisons.
Winter RJ; Sheehan Y; Papaluca T; Macdonald GA; Rowland J; Colman A; Stoove M; Lloyd AR; Thompson AJ
Med J Aust; 2023 Mar; 218(5):231-237. PubMed ID: 36871200
[TBL] [Abstract][Full Text] [Related]
8. "You need a designated officer" - Recommendations from correctional and justice health personnel for scaling up hepatitis C treatment-as-prevention in the prison setting.
Lafferty L; Rance J; Byrne M; Milat A; Dore GJ; Grebely J; Lloyd AR; Treloar C;
Int J Drug Policy; 2022 Aug; 106():103746. PubMed ID: 35636069
[TBL] [Abstract][Full Text] [Related]
9. Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian 'surveillance and treatment of prisoners with hepatitis C' project (SToP-C).
Rance J; Lafferty L; Treloar C;
Harm Reduct J; 2021 Apr; 18(1):46. PubMed ID: 33902595
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of treatment for hepatitis C in prisoners using a nurse-led, statewide model of care.
Papaluca T; McDonald L; Craigie A; Gibson A; Desmond P; Wong D; Winter R; Scott N; Howell J; Doyle J; Pedrana A; Lloyd A; Stoove M; Hellard M; Iser D; Thompson A
J Hepatol; 2019 May; 70(5):839-846. PubMed ID: 30654067
[TBL] [Abstract][Full Text] [Related]
11. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
[TBL] [Abstract][Full Text] [Related]
12. Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison.
Lafferty L; Rance J; Grebely J; Lloyd AR; Dore GJ; Treloar C;
J Viral Hepat; 2018 Dec; 25(12):1526-1532. PubMed ID: 30141261
[TBL] [Abstract][Full Text] [Related]
13. Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe.
Stöver H; Meroueh F; Marco A; Keppler K; Saiz de la Hoya P; Littlewood R; Wright N; Nava F; Alam F; Walcher S; Somaini L
BMC Public Health; 2019 Jan; 19(1):30. PubMed ID: 30621658
[TBL] [Abstract][Full Text] [Related]
14. Incidence of hepatitis C virus infection in the prison setting: The SToP-C study.
Hajarizadeh B; Carson JM; Byrne M; Grebely J; Cunningham E; Amin J; Vickerman P; Martin NK; Treloar C; Martinello M; Lloyd AR; Dore GJ;
J Viral Hepat; 2024 Jan; 31(1):21-34. PubMed ID: 37936544
[TBL] [Abstract][Full Text] [Related]
15. Violence and hepatitis C transmission in prison-A modified social ecological model.
Sazzad HMS; McCredie L; Treloar C; Lloyd AR; Lafferty L
PLoS One; 2020; 15(12):e0243106. PubMed ID: 33259565
[TBL] [Abstract][Full Text] [Related]
16. Impact of 5 years of hepatitis C testing and treatment in the North East of England prisons.
Johnson A; Shearer J; Thompson C; Jelley R; Aldridge J; Allsop C; Kerry J; Jones D; McCullough F; Miller C; Valappil M; Taha Y; Masson S; Jefferson T; Lawton C; Christensen L; McPherson S
J Viral Hepat; 2023 Dec; 30(12):914-921. PubMed ID: 37700492
[TBL] [Abstract][Full Text] [Related]
17. Acquiring hepatitis C in prison: the social organisation of injecting risk.
Treloar C; McCredie L; Lloyd AR;
Harm Reduct J; 2015 Apr; 12():10. PubMed ID: 25903401
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in Prisons.
Lim AG; Stone J; Hajarizadeh B; Byrne M; Chambers GM; Martin NK; Grebely J; Dore GJ; Lloyd AR; Vickerman P
Hepatology; 2021 Nov; 74(5):2366-2379. PubMed ID: 34105797
[TBL] [Abstract][Full Text] [Related]
19. Reducing barriers to the hepatitis C care cascade in prison via point-of-care RNA testing: a qualitative exploration of men in prison using an integrated framework.
Lafferty L; Sheehan Y; Cochrane A; Grebely J; Lloyd AR; Treloar C
Addiction; 2023 Jun; 118(6):1153-1160. PubMed ID: 36683132
[TBL] [Abstract][Full Text] [Related]
20. Who goes first? Understanding hepatitis C risk among injecting networks in the prison setting.
Lafferty L; Rance J; Treloar C
Drug Alcohol Depend; 2018 Feb; 183():96-101. PubMed ID: 29245104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]